Was the flu drug zanamivir a breakthrough or money for old rope? While Relenza's benefits are modest at best, its story would make a great Hollywood blockbuster

Research output: Contribution to journalComment/debateResearchpeer-review

1 Citation (Scopus)
Original languageEnglish
Article numberg3611
Number of pages2
JournalBritish Medical Journal
Volume348
DOIs
Publication statusPublished - 2 Jun 2014

Cite this

@article{6dde79d9a2bb4ed98c818f3a2882c8f6,
title = "Was the flu drug zanamivir a breakthrough or money for old rope?: While Relenza's benefits are modest at best, its story would make a great Hollywood blockbuster",
author = "Ray Moynihan",
year = "2014",
month = "6",
day = "2",
doi = "10.1136/bmj.g3611",
language = "English",
volume = "348",
journal = "BMJ (Clinical research ed.)",
issn = "0959-535X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Was the flu drug zanamivir a breakthrough or money for old rope?

T2 - While Relenza's benefits are modest at best, its story would make a great Hollywood blockbuster

AU - Moynihan, Ray

PY - 2014/6/2

Y1 - 2014/6/2

UR - http://www.scopus.com/inward/record.url?scp=84902149171&partnerID=8YFLogxK

U2 - 10.1136/bmj.g3611

DO - 10.1136/bmj.g3611

M3 - Comment/debate

VL - 348

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

SN - 0959-535X

M1 - g3611

ER -